| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 01, 2019 |
Former Chief Financial Officer
Trans History: 5
|
Former Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 60,000 | -- | 60,000 |
| Jan 18, 2019 |
Chief Operating Officer
Trans History: 22
|
Chief Operating Officer | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,000 | $1.30 | 6,815 |
| Jan 18, 2019 |
Chief Operating Officer
Trans History: 22
|
Chief Operating Officer | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,000 | -- | 28,219 |
| Dec 28, 2018 |
Ten Percent Owner
Trans History: 2
|
Ten Percent Owner | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | 975,000 |
| Dec 28, 2018 |
Ten Percent Owner
Trans History: 2
|
Ten Percent Owner | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Oct 01, 2018 |
Director
Trans History: 19
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,516 | -- | 10,516 |
| Oct 01, 2018 |
Chief Operating Officer
Trans History: 22
|
Chief Operating Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 59,590 | -- | 59,590 |
| Oct 01, 2018 |
Director
Trans History: 2
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,516 | -- | 10,516 |
| Oct 01, 2018 |
Chief Scientific Officer
Trans History: 21
|
Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 23,230 | -- | 23,230 |
| Oct 01, 2018 |
Director, President and CEO
Trans History: 32
|
Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 256,540 | -- | 256,540 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.